Enanta Pharmaceuticals, Inc.
ENTA
$8.67
$0.020.23%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.91% | -12.48% | -5.80% | -22.84% | -4.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.91% | -12.48% | -5.80% | -22.84% | -4.88% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.91% | -12.48% | -5.80% | -22.84% | -4.88% |
| SG&A Expenses | -25.47% | -20.00% | -22.23% | -0.81% | 6.31% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -11.74% | -20.81% | -23.42% | -11.01% | -24.19% |
| Operating Income | 21.88% | 25.14% | 32.51% | 3.79% | 34.12% |
| Income Before Tax | 20.94% | 24.02% | 33.27% | 1.12% | 33.84% |
| Income Tax Expenses | 107.34% | -259.50% | 33.12% | 74.26% | -109.36% |
| Earnings from Continuing Operations | 19.43% | 27.32% | 33.28% | -2.55% | 42.00% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.43% | 27.32% | 33.28% | -2.55% | 42.00% |
| EBIT | 21.88% | 25.14% | 32.51% | 3.79% | 34.12% |
| EBITDA | 25.04% | 27.44% | 33.85% | 3.25% | 34.58% |
| EPS Basic | 20.17% | 27.96% | 33.75% | -1.90% | 42.34% |
| Normalized Basic EPS | 21.67% | 24.69% | 35.07% | 6.92% | 34.23% |
| EPS Diluted | 20.17% | 27.96% | 33.75% | -1.90% | 42.34% |
| Normalized Diluted EPS | 21.67% | 24.69% | 35.07% | 6.92% | 34.23% |
| Average Basic Shares Outstanding | 0.93% | 0.89% | 0.71% | 0.63% | 0.60% |
| Average Diluted Shares Outstanding | 0.93% | 0.89% | 0.71% | 0.63% | 0.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |